Brainstorm Cell Therapeutics Inc. (BCLI) Earnings History
Net Loss25 years of earnings data (2001–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Brainstorm Cell Therapeutics Inc. (BCLI) Earnings Overview
As of June 23, 2026, Brainstorm Cell Therapeutics Inc. (BCLI) reported trailing twelve-month net income of -$10M, reflecting -150.7% year-over-year growth. The company earned $-0.87 per diluted share over the past four quarters.
Looking at the long-term picture, BCLI's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2024.
Brainstorm Cell Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CLLS (-$67M net income, -92.7% margin), FATE (-$130M net income, -2051.1% margin), AGEN ($65M net income, 0.1% margin), BCLI has comparable earnings metrics. Compare BCLI vs CLLS →
BCLI Earnings vs Peers
Earnings metrics vs comparable public companies
BCLI Historical Earnings Data (2001–2025)
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$10M | -188.7% | -$10M | $-1.11 | - | - |
| 2024 | $12M | +167.6% | -$12M | $2.19 | - | - |
| 2023 | -$17M | +29.2% | -$21M | $-4.48 | - | - |
| 2022 | -$24M | +0.7% | -$25M | $-9.93 | - | - |
| 2021 | -$24M | +23.1% | -$25M | $-10.09 | - | - |
| 2020 | -$32M | -36.8% | -$32M | $-14.09 | - | - |
| 2019 | -$23M | -66.7% | -$23M | $-13.64 | - | - |
| 2018 | -$14M | -181.7% | -$14M | $-10.05 | - | - |
| 2017 | -$5M | +0.6% | -$5M | $-3.92 | - | - |
| 2016 | -$5M | +41.3% | -$5M | $-4.00 | - | - |
| 2015 | -$8M | +8.2% | -$9M | $-6.88 | - | - |
| 2014 | -$9M | -88.7% | -$7M | $-8.31 | - | - |
| 2013 | -$5M | -42.8% | -$5M | $-0.46 | - | - |
| 2012 | -$3M | +12.5% | -$4M | $-0.37 | - | - |
| 2011 | -$4M | -62.0% | -$4M | $-0.49 | - | - |
| 2010 | -$2M | -35.8% | -$3M | $-0.41 | - | - |
| 2009 | -$2M | +48.7% | -$2M | $-0.44 | - | - |
| 2008 | -$3M | +44.4% | -$3M | $-1.06 | - | - |
| 2007 | -$6M | -59.1% | -$5M | $-3.20 | - | - |
| 2006 | -$4M | +79.2% | -$3M | $-2.48 | - | - |
| 2004 | -$19M | -25604.1% | -$19M | $-15.20 | - | - |
| 2003 | $-73,295 | -56.6% | $-70,947 | $-0.06 | - | - |
| 2002 | $-46,806 | -83.1% | $-46,806 | $-0.03 | -56.5% | -56.5% |
| 2001 | $-25,560 | - | $-32,689 | $-0.14 | -111.6% | -142.7% |
Download Data
Export BCLI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BCLI — Frequently Asked Questions
Quick answers to the most common questions about buying BCLI stock.
What is BCLI earnings per share (EPS)?
BCLI trailing twelve-month (TTM) diluted EPS is $-0.87, reflecting -150.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2001 to 2025 is available in the table on this page.
What is Brainstorm Cell Therapeutics Inc.'s net income?
Brainstorm Cell Therapeutics Inc. (BCLI) trailing twelve-month net income is $-10M as of 2025. Earnings declined -150.7% year-over-year.
Is BCLI profitable?
BCLI is not currently profitable on a TTM basis, reporting a net loss of $-10M. Net margin is N/A. Investors should monitor for a return to profitability.
What is BCLI's earnings growth rate?
BCLI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2001 to 2025.
What are BCLI's profit margins?
Brainstorm Cell Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is BCLI growing earnings?
BCLI earnings are declining — EPS fell -150.7% year-over-year. TTM net income dropped to $-10M. This contrasts with the 5-year CAGR of N/A.
What was BCLI's best earnings year?
Brainstorm Cell Therapeutics Inc.'s highest annual net income on record is $12M, achieved in fiscal year 2024. Earnings history on this page spans 2001 to 2025 and includes all annual and quarterly figures.
What were BCLI's earnings last quarter?
BCLI's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.19. For a full breakdown of all quarters, see the quarterly earnings table on this page.